<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Growth opportunities include wider global adoption and NGF-platform expansion into dry eye, optic neuropathy and other ocular disordersDublin, Sept. 10, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6274376/oxervate-sales-forecast-market-size-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=fsjjtt&amp;utm_campaign=2348679+-+OXERVATE+Clinical%2c+Commercial+and+Competitive+Analysis+with+Sales+Forecast+to+2034&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="OXERVATE Sales Forecast, and Market Size Analysis - 2034">"OXERVATE Sales Forecast, and Market Size Analysis - 2034"</a> has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of OXERVATE (cenegermin-bkbj) across the seven major pharmaceutical markets: the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. Covering the 2020-2034 study period, the report evaluates historical performance, current market dynamics, and forecast sales for OXERVATE in neurotrophic keratitis, alongside its potential development across additional ophthalmic indications. Developed by Dompe, OXERVATE is a recombinant human nerve growth factor ophthalmic solution approved for neurotrophic keratitis. The therapy is administered topically six times daily for eight weeks and is designed to restore corneal innervation, support epithelial proliferation, and promote corneal healing. As the first and only FDA-approved treatment for neurotrophic keratitis, OXERVATE holds a differentiated position within the rare ophthalmic disease market. Key Factors Supporting OXERVATE Market Growth <ul><li>First-in-class status and limited direct competition in neurotrophic keratitis.</li><li>A novel nerve growth factor-based mechanism that targets corneal nerve regeneration and tissue integrity.</li><li>Clinical trial results showing approximately 72% complete corneal healing at eight weeks, compared with approximately 33% for placebo.</li><li>Durable treatment response, with approximately 80% of responders remaining healed at one year.</li><li>Orphan Drug, Fast Track, and Breakthrough Therapy designations supporting development and commercialization.</li><li>Rare disease market exclusivity, premium pricing potential, and an established reimbursement framework.</li><li>Opportunities for lifecycle expansion across dry eye disease, corneal nerve disorders, ischemic optic neuropathy, glaucoma, and retinitis pigmentosa.</li></ul> OXERVATE is recognized as a high-cost specialty therapy, with reported treatment costs reaching tens of thousands of US dollars for an eight-week course. Its commercial outlook is influenced by diagnosis rates, specialist adoption, payer coverage, treatment access, regional pricing, and the emergence of competing therapies. Recent OXERVATE Development In October 2025, Dompe announced that an intranasal cenegermin-bkbj formulation had been selected for the FDA Commissioner's National Priority Voucher program. The program is intended to expedite development for non-arteritic anterior ischemic optic neuropathy and extends the potential application of Dompe's nerve growth factor platform beyond OXERVATE's approved ophthalmic use. OXERVATE Market Report Scope The report presents an integrated commercial, clinical, regulatory, and competitive analysis of OXERVATE. It examines the product's mechanism of action, dosage and administration, research and development activities, regulatory milestones, patent landscape, potential generic entry, pricing trends, reimbursement conditions, and regional cost variations. Current and forecast OXERVATE sales through 2034 are assessed for neurotrophic keratitis and potential indications, including dry eye disease, glaucoma, ischemic optic neuropathy, and retinitis pigmentosa. The analysis also evaluates peak sales potential, market positioning, adoption trends, competitive risks, and the assumptions influencing revenue forecasts across the seven major markets. <ul><li>Historical, current, and forecast OXERVATE sales by geography and indication.</li><li>Market size analysis and peak revenue potential through 2034.</li><li>Clinical trial activity, including interventions, trial status, and expected completion dates.</li><li>Regulatory approvals, designations, development milestones, and anticipated launch timelines.</li><li>OXERVATE pricing strategies, treatment costs, reimbursement access, and regional variations.</li><li>Patent information, exclusivity considerations, and potential impact of generic competition.</li><li>Competitive intelligence covering marketed products and late-stage emerging therapies.</li><li>SWOT analysis supported by analyst perspectives on clinical and commercial performance.</li><li>Commercial partnerships, licensing agreements, mergers, acquisitions, and related strategic activity.</li></ul> Competitive and Clinical Assessment The OXERVATE competitive landscape analysis reviews existing treatments, pipeline candidates, expected launch dates, and potential threats to market share. It compares OXERVATE's efficacy, safety, clinical differentiation, route of administration, and market positioning with current and emerging ophthalmic therapies. The clinical assessment covers OXERVATE trials across approved and investigational indications, including study design, trial conditions, development status, and projected completion timelines. This analysis is designed to clarify how future clinical outcomes and regulatory decisions may affect adoption, pricing, competitive positioning, and sales performance. Market Outlook OXERVATE market growth is expected to be supported by increasing diagnosis of neurotrophic keratitis, greater specialist awareness, prescription growth, and potential expansion into additional ophthalmic indications. However, future performance will also depend on treatment affordability, reimbursement policies, patient access, prescribing requirements, and competition from late-stage pipeline therapies. The report enables pharmaceutical companies, investors, market access teams, and other stakeholders to evaluate OXERVATE's long-term commercial potential. Its forecast analysis supports therapeutic portfolio planning, competitive benchmarking, pricing strategy, market entry assessment, and strategic decision-making through 2034. Key Questions Addressed <ul><li>What are OXERVATE's current and forecast sales across the United States, Europe, the United Kingdom, and Japan?</li><li>Which clinical, regulatory, pricing, and reimbursement factors will drive OXERVATE market growth through 2034?</li><li>How does OXERVATE compare with marketed products and emerging ophthalmic therapies?</li><li>What is the development status of OXERVATE across approved and potential indications?</li><li>How could patent expiry, generic entry, and pipeline competition affect future revenue?</li><li>What are the principal opportunities and barriers influencing OXERVATE's peak sales potential?</li></ul> Key Topics Covered 1. Report Introduction 2. OXERVATE Overview in approved indications like Keratitis; as well as potential indication like Dry eyes, Glaucoma, Ischaemic optic neuropathy, and Retinitis pigmentosa 2.1. Product Detail 2.2. OXERVATE Clinical Development 2.2.1. OXERVATE Clinical studies 2.2.2. OXERVATE Clinical trials information 2.2.3. Safety and efficacy 2.3. Other Developmental Activities 2.4. Product Profile 3. OXERVATE Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging OXERVATE Therapies) 5. OXERVATE Market Assessment 5.1. OXERVATE Market Outlook in approved and potential indications 5.2. 7MM Analysis 5.2.1. OXERVATE Market Size in the 7MM for approved and potential indications 5.3. Country-wise Market Analysis 5.3.1. OXERVATE Market Size in the United States for approved and potential indications 5.3.2. OXERVATE Market Size in Germany for approved and potential indications 5.3.3. OXERVATE Market Size in France for approved and potential indications 5.3.4. OXERVATE Market Size in Italy for approved and potential indications 5.3.5. OXERVATE Market Size in Spain for approved and potential indications 5.3.6. OXERVATE Market Size in the United Kingdom for approved and potential indications 5.3.7. OXERVATE Market Size in Japan for approved and potential indications 6. OXERVATE SWOT Analysis 7. Analysts' Views 8. Appendix 8.1. Bibliography 8.2. Report Methodology List of Tables Table 1: OXERVATE, Clinical Trial Description, 2023 Table 2: OXERVATE, General Description Table 3: Competitive Landscape (Marketed Therapies) Table 4: Competitive Landscape (Emerging Therapies) Table 5: OXERVATE's pricing and cost Assumptions Table 6: OXERVATE's Sales Analysis in the 7MM, in USD million (2020-2034) Table 7: OXERVATE Market Size in the US, in USD million (2020-2034) Table 8: OXERVATE Market Size in Germany, in USD million (2020-2034) Table 9: OXERVATE Market Size in France, in USD million (2020-2034) Table 10: OXERVATE Market Size in Italy, in USD million (2020-2034) Table 11: OXERVATE Market Size in Spain, in USD million (2020-2034) Table 12: OXERVATE Market Size in the UK, in USD million (2020-2034) Table 13: OXERVATE Market Size in Japan, in USD million (2020-2034) List of Figures Figure 1: OXERVATE's Sales Analysis in the 7MM, USD million (2020-2034) Figure 2: OXERVATE Market Size in the United States, USD million (2020-2034) Figure 3: OXERVATE Market Size in Germany, USD million (2020-2034) Figure 4: OXERVATE Market Size in France, USD million (2020-2034) Figure 5: OXERVATE Market Size in Italy, USD million (2020-2034) Figure 6: OXERVATE Market Size in Spain, USD million (2020-2034) Figure 7: OXERVATE Market Size in the United Kingdom, USD million (2020-2034) Figure 8: OXERVATE Market Size in Japan, USD million (2020-2034) For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6274376/oxervate-sales-forecast-market-size-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=fsjjtt&amp;utm_campaign=2348679+-+OXERVATE+Clinical%2c+Commercial+and+Competitive+Analysis+with+Sales+Forecast+to+2034&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/exnqih</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NTQ5YWMwNmUtZmU4ZS00MWQ5LWJiYWEtMmQ4NTRjYmRhZWZhLTEwMjY3MzctMjAyNi0wOS0xMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

OXERVATE Clinical, Commercial and Competitive Analysis with Sales Forecast to 2034

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn